Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex.
Perturbations in the integrity of the blood-brain barrier have been reported in both humans and animals under numerous pathological conditions. Although the blood-brain barrier prevents the penetration of many blood constituents into the brain extracellular space, the effect of such perturbations on the brain function and their roles in the pathogenesis of cortical diseases are unknown. In this study we established a model for focal disruption of the blood-brain barrier in the rat cortex by direct application of bile salts. Exposure of the cerebral cortex in vivo to bile salts resulted in long-lasting extravasation of serum albumin to the brain extracellular space and was associated with a prominent activation of astrocytes with no inflammatory response or marked cell loss. Using electrophysiological recordings in brain slices we found that a focus of epileptiform discharges developed within 4-7 d after treatment and could be recorded up to 49 d postoperatively in >60% of slices from treated animals but only rarely (10%) in sham-operated controls. Epileptiform activity involved both glutamatergic and GABAergic neurotransmission. Epileptiform activity was also induced by direct cortical application of native serum, denatured serum, or albumin-containing solution. In contrast, perfusion with serum-adapted electrolyte solution did not induce abnormal activity, thereby suggesting that the exposure of the serum-devoid brain environment to serum proteins underlies epileptogenesis in the blood-brain barrier-disrupted cortex. Although many neuropathologies entail a compromised blood-brain barrier, this is the first direct evidence that it may have a role in the pathogenesis of focal cortical epilepsy, a common neurological disease.
Seiffert
Ernst
E
Johannes-Müller-Institute of Physiology, Charité, University Medicine, 10117 Berlin, Germany.
Dreier
Jens P
JP
Ivens
Sebastian
S
Bechmann
Ingo
I
Tomkins
Oren
O
Heinemann
Uwe
U
Friedman
Alon
A
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D001647:Bile Acids and Salts / Q000633:toxicity*; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000502:physiology; D004396:Coloring Agents / Q000493:pharmacokinetics; D003685:Dehydrocholic Acid / Q000633:toxicity; D003840:Deoxycholic Acid / Q000633:toxicity; D004594:Electrophysiology; D004828:Epilepsies, Partial / Q000139:chemically induced* / Q000503:physiopathology; D005070:Evans Blue / Q000493:pharmacokinetics; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000502:physiology; D008297:Male; D010539:Permeability; D051381:Rats; D017208:Rats, Wistar; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors; D018079:Receptors, GABA / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D044967:Serum; D012709:Serum Albumin / Q000633:toxicity; D013003:Somatosensory Cortex / Q000503:physiopathology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D001647:Bile Acids and Salts; D004396:Coloring Agents; D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; D018079:Receptors, GABA; D016194:Receptors, N-Methyl-D-Aspartate; D012709:Serum Albumin; D003840:Deoxycholic Acid; D018698:Glutamic Acid; D005070:Evans Blue; D005680:gamma-Aminobutyric Acid; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D015763:2-Amino-5-phosphonovalerate; D003685:Dehydrocholic Acid; D001640:Bicuculline